Coronary microvascular dysfunction and prognosis in hypertrophic cardiomyopathy

New England Journal of Medicine

Volumn 349, Issue 11, 2003, Pages 1027-1035

  Cecchi, Franco ^a,f   Olivotto, Iacopo ^a   Gistri, Roberto ^a   Lorenzoni, Roberto ^b   Chiriatti, Giampaolo ^c   Camici, Paolo G ^d,e  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Ospedale di Lucca   (Italy)

^c Ospedale di Pescia   (Italy)

^d CNR   (Italy)

^e HAMMERSMITH HOSPITAL   (United Kingdom)

^f NONE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMMONIA; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIPYRIDAMOLE; DIURETIC AGENT; NITROGEN 13; VASODILATOR AGENT; VERAPAMIL;

ADULT; ARTICLE; CAUSE OF DEATH; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; CORONARY BLOOD VESSEL; DEFIBRILLATOR; DISEASE ACTIVITY; DISEASE CLASSIFICATION; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFECT; DRUG INFUSION; FEMALE; HEART VENTRICLE ARRHYTHMIA; HUMAN; HYPERTROPHIC CARDIOMYOPATHY; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; PROSPECTIVE STUDY; RISK ASSESSMENT; VASODILATATION; ANALYSIS OF VARIANCE; COMPUTER ASSISTED EMISSION TOMOGRAPHY; ECHOGRAPHY; FOLLOW UP; MICROCIRCULATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; ROC CURVE; SURVIVAL;

ADULT; ANALYSIS OF VARIANCE; CARDIOMYOPATHY, HYPERTROPHIC; COHORT STUDIES; CORONARY CIRCULATION; DIPYRIDAMOLE; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MICROCIRCULATION; MIDDLE AGED; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; ROC CURVE; SURVIVAL ANALYSIS; TOMOGRAPHY, EMISSION-COMPUTED; VASODILATOR AGENTS;

EID: 0041385743     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa025050     Document Type: Article

References (36)

1. Maron BJ. Hypertrophic cardiomyopathy: a systematic review. JAMA 2002;287:1308-20.
2. Spirito P, Seidman CE, McKenna WJ, Maron BJ. The management of hypertrophic cardiomyopathy. N Engl J Med 1997;336:775-85.
3. Maron BJ, Wolfson JK, Epstein SE, Roberts WC. Intramural ("small vessel") coronary artery disease in hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;8:545-57.
4. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J 1986;55:575-81.
5. Schwartzkopff B, Mundhenke M, Strauer BE. Alterations of the architecture of subendocardial arterioles in patients with hypertrophic cardiomyopathy and impaired coronary vasodilator reserve: a possible cause for myocardial ischemia. J Am Coll Cardiol 1998;31:1089-96.
6. McKenna WJ, Stewart JT, Nihoyannopoulos P, McGinty F, Davies MJ. Hypertrophic cardiomyopathy without hypertrophy: two families with myocardial disarray in the absence of increased myocardial mass. Br Heart J 1990;63:287-90.
7. Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:988-98.
8. Elliott PM, Poloniecki J, Dickie S, et al. Sudden death in hypertrophic cardiomyopathy: identification of high risk patients. J Am Coll Cardiol 2000;36:2212-8.
9. Spirito P, Bellone P, Harris KM, Bernabò P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:1778-85.
10. Elliott PM, Gimeno Blanes JR, Mahon NG, Poloniecki JD, McKenna WJ. Relation between severity of left-ventricular hypertrophy and prognosis in patients with hypertrophic cardiomyopathy. Lancet 2001;357:420-4.
11. Olivotto I, Gistri R, Petrone P, Pedemonte E, Vargiu D, Cecchi F. Maximum left ventricular thickness and risk of sudden death in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2003;41:315-21.
12. Cecchi F, Olivotto I, Montereggi A, Santoro G, Dolara A, Maron BJ. Hypertrophic cardiomyopathy in Tuscany: clinical course and outcome in an unselected regional population. J Am Coll Cardiol 1995;26:1529-36.
13. Maron BJ, Olivotto I, Spirito P, et al. Epidemiology of hypertrophic cardiomyopathy-related death: revisited in a large non-referral-based patient population. Circulation 2000;102:858-64.
14. Maron MS, Olivotto I, Betocchi S, et al. Effect of left ventricular outflow tract obstruction on clinical outcome in hypertrophic cardiomyopathy. N Engl J Med 2003;348:295-303.
15. Maron BJ, Shen W-K, Link MS, et al. Efficacy of implantable cardioverter-defibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med 2000;342:365-73.
16. Camici PG, Chiriatti G, Lorenzoni R, et al. Coronary vasodilation is impaired in both hypertrophied and nonhypertrophied myocardium of patients with hypertrophic cardiomyopathy: a study with nitrogen-13 ammonia and positron emission tomography. J Am Coll Cardiol 1991;17:879-86.
17. Camici PG, Cecchi F, Gistri R, et al. Dipyridamole-induced subendocardial under-perfusion in hypertrophic cardiomyopathy assessed by positron emission tomography. Coronary Artery Dis 1991;2:837-41.
18. Choudhury L, Elliott P, Rimoldi O, et al. Transmural myocardial blood flow distribudon in hypertrophic cardiomyopathy and effect of treatment. Basic Res Cardiol 1999;94:49-59.
19. Lorenzoni R, Gistri R, Cecchi F, et al. Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction. Am Heart J 1998;136:972-81.
20. Dilsizian V, Bonow RO, Epstein SE, Fananapazir L. Myocardial ischemia detected by thallium scintigraphy is frequently related to cardiac arrest and syncope in young patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1993;22:796-804.
21. Lazzeroni E, Picano E, Morozzi L, et al. Dipyridamole-induced ischemia as a prognostic marker of future adverse cardiac events in adult patients with hypertrophic cardiomyopathy. Circulation 1997;96:4268-72.
22. Yoshida N, Ikeda H, Wada T, et al. Exercise-induced abnormal blood pressure responses are related to subendocardial ischemia in hypertrophic cardiomyopathy. J Am Coll Cardiol 1998;32:1938-42.
23. O'Gara PT, Bonow RO, Maron BJ, et al. Myocardial perfusion abnormalities in patients with hypertrophic cardiomyopathy: assessment with thallium-201 emission computed tomography. Circulation 1987;76:1214-23.
24. Cannon RO III, Dilsizian V, O'Gara PT, et al. Myocardial metabolic, hemodynamic, and electrocardiographic significance of reversible thallium-201 abnormalities in hypertrophic cardiomyopathy. Circulation 1991;83:1660-7.
25. Cannon RO III, Rosing DR, Maron BJ, et al. Myocardial ischaemia in patients with hypertrophic cardiomyopathy: contribution of inadequate vasodilator reserve and elevated left ventricular filling pressures. Circulation 1985;71:234-43.
26. Elliott PM, Kaski JC, Prasad K, et al. Chest pain during daily life in patients with hypertrophic cardiomyopathy: an ambulatory electrocardiographic study. Eur Heart J 1996;17:1056-64.
27. Krams R, Kofflard MJ, Duncker DJ, et al. Decreased coronary flow reserve in hypertrophic cardiomyopathy is related to remodeling of the coronary microcirculation. Circulation 1998;97:230-3.
28. Gistri K, Cecchi F, Choudhury L, et al. Effect of verapamil on absolute myocardial blood flow in hypertrophic cardiomyopathy. Am J Cardiol 1994;74:363-8.
29. Udelson JE, Bonow RO, O'Gara PT, et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79:1052-60.
30. Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:2517-24.
31. Stafford WJ, Trohman RG, Bilsker M, Zaman L, Castellanos A, Myerburg RJ. Cardiac arrest in an adolescent with atrial fibrillation and hypertrophic cardiomyopathy. J Am Coll Cardiol 1986;7:701-4.
32. Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of the distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy: a wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:418-28.
33. Choudhury L, Rosen S, Patel D, Nihoyannopoulos P, Camici PG. Coronary vasodilator reserve in primary and secondary left ventricular hypertrophy: a study with positron emission tomography. Eur Heart J 1997;18:108-16.
34. Rajappan K, Rimoldi OE, Dutka DP, et al. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 2002;105:470-6.
35. Neglia D, Michelassi C, Trivieri MG, et al. Prognostic role of myocardial blood flow impairment in idiopathic left ventricular dysfunction. Circulation 2002;105:186-93.
36. Gnecchi-Ruscone T, Taylor J, Mercuri E, et al. Cardiomyopathy in Duchenne, Becker and sarcoglycanopathies: a role for coronary dysfunction? Muscle Nerve 1999;22:1549-56.